Evidence map›Paper›PMID 31573603›Full record

ArticleThe Journal of infectious diseases2020

Nonoptimal Vaginal Microbiota After Azithromycin Treatment for Chlamydia trachomatis Infection.

Jeanne Tamarelle, Bing Ma, Pawel Gajer, Mike S Humphrys, Mishka Terplan, Katrina S Mark, Anne C M Thiébaut, Larry J Forney, Rebecca M Brotman, Elisabeth Delarocque-Astagneau and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Cervicovaginal Microbiota Composition inInternational journal of molecular sciences · 2022
    Pooled it
  2. Review
  3. Vaginal formulations selectively target Lactobacillus iners and Candida spp. while preserving Lactobacillus crispatus.International microbiology : the official journal of the Spanish Society for Microbiology · 2026
    Article
  4. Article
  5. Repurposing epetraborole to combatAntimicrobial agents and chemotherapy · 2026
    Article
  6. Article
  7. Article
  8. iScience · 2025
    Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. International journal of systematic and evolutionary microbiology · 2023
    Article
  14. Article
  15. Current infectious disease reports · 2023
    Article
  16. Article
  17. Interactions between microbiota and cervical epithelial, immune, and mucus barrier.Frontiers in cellular and infection microbiology · 2023
    Review
  18. Article
  19. Recent Advances in Treatment of Recurrent Spontaneous Abortion.Obstetrical & gynecological survey · 2022
    Review
  20. Towards a Deeper Understanding ofInternational journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Jeanne TamarelleUnité Mixte de Recherche 1181 , Université Versailles-Saint-Quentin-en-Yvelines, Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Paris, France.
Bing MaInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Pawel GajerInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Mike S HumphrysInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Mishka TerplanDepartment of Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore, Maryland, USA, Department of Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Katrina S MarkDepartment of Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore, Maryland, USA, Department of Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Anne C M ThiébautUnité Mixte de Recherche 1181 , Université Versailles-Saint-Quentin-en-Yvelines, Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Paris, France.
Larry J ForneyDepartment of Biological Sciences, University of Idaho, Moscow, Idaho, USA.
Rebecca M BrotmanInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Elisabeth Delarocque-AstagneauUnité Mixte de Recherche 1181 , Université Versailles-Saint-Quentin-en-Yvelines, Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Paris, France.
Patrik M BavoilDepartment of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, Maryland, USA.
Jacques RavelInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
University of Maryland, Baltimore · USInserm · FRUniversity of Idaho · US

Funding

Serologic Biomarkers of Human Sexually Transmitted Infection and DiseaseU19AI084044 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI TETTELIN, HERVE S · 2009 to 2018
$22.8M
The Microbial Ecology of Bacterial Vaginosis: A Fine Scale Resolution MetagenomicUH2AI083264 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI RAVEL, JACQUES · 2009 to 2011
$1.9M
The interaction between vaginal microbiota, immunogenetics and C. trachomatis susceptibilityR21AI130627 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI DELAROCQUE-ASTAGNEAU, ELISABETH, RAVEL, JACQUES · 2018 to 2019
$371k
NIAID NIH HHS R21 AI130627NIAID NIH HHS U19 AI084044NIAID NIH HHS UH2 AI083264
6 · The paper itself

Abstract

We characterized the composition and structure of the vaginal microbiota in a cohort of 149 women with genital Chlamydia trachomatis infection at baseline who were followed quarterly for 9 months after antibiotic treatment. At time of diagnosis, the vaginal microbiota was dominated by Lactobacillus iners or a diverse array of bacterial vaginosis-associated bacteria including Gardnerella vaginalis. Interestingly, L. iners-dominated communities were most common after azithromycin treatment (1 g monodose), consistent with the observed relative resistance of L. iners to azithromycin. Lactobacillus iners-dominated communities have been associated with increased risk of C. trachomatis infection, suggesting that the impact of antibiotic treatment on the vaginal microbiota could favor reinfections. These results provide support for the dual need to account for the potential perturbing effect(s) of antibiotic treatment on the vaginal microbiota, and to develop strategies to protect and restore optimal vaginal microbiota.

Indexed as

AdolescentAdultAnti-Bacterial AgentsAzithromycinChlamydia InfectionsChlamydia trachomatisCross-Sectional StudiesFemaleFollow-Up StudiesGardnerella vaginalisHumansLactobacillusMicrobiotaProspective StudiesRNA, Ribosomal, 16STreatment OutcomeAnti-Bacterial AgentsAzithromycinRNA, Ribosomal, 16S16S rRNA gene sequencingantibioticsChlamydia trachomatislongitudinalsexually transmitted infectionvaginal microbiome

Identifiers

PMID31573603
PMCPMC7530545
OpenAlexW2979065087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.